Jaguar Health: MVID Milestone Achieved, But Liquidity Crisis Remains

What happened

Jaguar Health announced the first pediatric MVID patient has entered the active-treatment extension phase of its pivotal trial, a step toward a potential NDA for crofelemer in this ultrarare disease. While this is a positive clinical signal, the company's fundamental financial distress is unchanged: it holds only $3.5M cash against $36.1M current liabilities, with a $27M annual minimum royalty burden beginning April 2026. The extension phase evaluates longer-term safety and efficacy, but even a successful NDA would require years to deliver meaningful revenue, far beyond the current cash runway. The DeepValue report maintains a STRONG SELL rating, emphasizing that equity value depends on a binding restructuring cutting 2026–2028 obligations by at least 50%, which has not materialized. Without such a restructuring or a large upfront partnership, the stock remains a distressed option with high probability of near-total capital loss.

Implication

Investors should treat this as a modest positive for pipeline value but not a reason to buy. The MVID data may improve the odds of a partnership, but the company needs a binding royalty restructuring before April 2026 to avoid catastrophic dilution or bankruptcy. Until that occurs, the likely path is continued equity dilution or a distressed recapitalization that wipes out common shareholders. The core thesis—that Jaguar's liabilities vastly outweigh its current revenue and near-term prospects—remains intact, and the risk/reward is heavily skewed to the downside. Any position should be sized for a total loss, with a re-assessment only if a comprehensive restructuring is announced.

Thesis delta

The thesis shift is minimal: the MVID extension adds credibility to the pipeline but does not address the solvency crunch. The bear case (55% probability of equity wipeout) now has a slightly lower tail risk due to improved regulatory visibility, but the base case remains severe dilution. The bull case (10%) gains a minor boost, but the fundamental financing gap persists.